Holen Sie sich die Stockscreener-App
75.95
3.40%
-2.67
Handel nachbörslich:
75.95
Schlusskurs vom Vortag:
$78.62
Offen:
$78.62
24-Stunden-Volumen:
1.04M
Relative Volume:
0.94
Marktkapitalisierung:
$4.72B
Einnahmen:
$209.18M
Nettoeinkommen (Verlust:
$52.04M
KGV:
106.60
EPS:
0.7125
Netto-Cashflow:
$37.10M
1W Leistung:
+0.93%
1M Leistung:
+17.15%
6M Leistung:
+66.89%
1J Leistung:
+62.43%
1-Tages-Spanne:
$75.53
$80.43
1-Wochen-Bereich:
$74.80
$80.43
52-Wochen-Spanne:
$33.31
$93.25
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Vergleichen Sie PTGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
75.95 | 4.89B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - ACCESS Newswire
Protagonist (PTGX) to present 4 rusfertide presentations at ASH, including Phase 3 VERIFY - Stock Titan
Is Protagonist Therapeutics Inc. stock entering bullish territoryMarket Weekly Review & Step-by-Step Trade Execution Guides - newser.com
Protagonist Therapeutics Inc. stock chart pattern explainedMarket Risk Summary & Fast Moving Market Watchlists - newser.com
How rising interest rates impact Protagonist Therapeutics Inc. stock2025 Key Lessons & Reliable Breakout Forecasts - newser.com
How Protagonist Therapeutics Inc. stock responds to policy changesJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
Leerink Partnrs Issues Optimistic Forecast for PTGX Earnings - MarketBeat
Can Protagonist Therapeutics Inc. hit a new high this month2025 Earnings Impact & Short-Term High Return Ideas - newser.com
How strong is Protagonist Therapeutics Inc. stock revenue growth2025 Momentum Check & Safe Capital Preservation Plans - newser.com
Price action breakdown for Protagonist Therapeutics Inc.July 2025 Recap & Free Fast Gain Swing Trade Alerts - newser.com
Is Protagonist Therapeutics Inc. stock a top pick in earnings season2025 Momentum Check & Weekly Return Optimization Alerts - newser.com
Protagonist Therapeutics, Inc. $PTGX is Moody Aldrich Partners LLC's 2nd Largest Position - MarketBeat
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Donaldsonville Chief
What is Wedbush's Estimate for PTGX FY2029 Earnings? - MarketBeat
Protagonist Therapeutics (PTGX) to Release Earnings on Thursday - MarketBeat
Will Protagonist Therapeutics Inc. stock benefit from commodity pricesProduct Launch & Daily Entry Point Alerts - newser.com
How Protagonist Therapeutics Inc. stock reacts to job market data2025 Market Outlook & Expert Curated Trade Setups - newser.com
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis and Plaque Psoriasis Presented at Two Recent Medical Conferences - Asbury Park Press
Protagonist Therapeutics (PTGX): Assessing Valuation After Breakthrough Phase 2b Results and Johnson & Johnson’s Phase 3 Launch - Sahm
Protagonist Therapeutics (PTGX) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
How to track smart money flows in Protagonist Therapeutics Inc.2025 Retail Activity & Risk Controlled Daily Trade Plans - newser.com
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $86.00 at Wedbush - MarketBeat
Protagonist Therapeutics (PTGX) Price Target Increased by 10.06% to 78.69 - Nasdaq
BTIG Research Reiterates "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
State of New Jersey Common Pension Fund D Sells 12,711 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Wedbush Maintains Protagonist Therapeutics (PTGX) Outperform Recommendation - Nasdaq
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.64%
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):